Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.71 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899601 | 1.00 | LGALS3 (0.71) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL20899615 | 0.93 | LGALS3 (0.60) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL20899616 | 0.93 | LGALS3 (0.60) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL20899004 | 0.93 | LGALS3 (0.64) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL20899003 | 0.93 | LGALS3 (0.64) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL20899373 | 0.89 | LGALS3 (0.71) | LGALS3 | |
| SCHEMBL20899372 | 0.89 | LGALS3 (0.71) | LGALS3 | |
| SCHEMBL20911330 | 0.88 | LGALS3 (0.69) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL19680619 | 0.88 | LGALS3 (0.69) | LGALS3LGALS9LGALS8LGALS1LGALS4 | |
| SCHEMBL17964160 | 0.88 | LGALS3 (0.69) | LGALS3LGALS9LGALS8LGALS1LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072626-B2 | Small molecule inhibitors of Galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072626-B2 | Small molecule inhibitors of Galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200308213-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308213-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2019075045-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308213-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS9 5/4885LGALS8 7/4885 |
| US-11072626-B2 | Small molecule inhibitors of Galectin-3 | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS9 5/4885LGALS8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.